Biology Reference
In-Depth Information
Menne J, Haller H, Fliser D (2004)
Erythropoietin regulates endothelial progeni-
tor cells. Blood 103:921-926
204. Heeschen C, Aicher A, Lehmann R,
Fichtlscherer S, Vasa M, Urbich C, Mildner-
Rihm C, Martin H, Zeiher AM, Dimmeler S
(2003) Erythropoietin is a potent physiologic
stimulus for endothelial progenitor cell mobi-
lization. Blood 102:1340-1346
205. Santhanam AV, d'Uscio LV, Peterson TE,
Katusic ZS (2008) Activation of endothelial
nitric oxide synthase is critical for erythropoi-
etin-induced mobilization of progenitor cells.
Peptides 29:1451-1455
206. Westenbrink BD, Lipsic E, van der Meer P,
van der Harst P, Oeseburg H, Du Marchie
Sarvaas GJ, Koster J, Voors AA, van Veldhuisen
DJ, van Gilst WH, Schoemaker RG (2007)
Erythropoietin improves cardiac function
through endothelial progenitor cell and vas-
cular endothelial growth factor mediated neo-
vascularization. Eur Heart J 28:2018-2027
207. Klopsch C, Furlani D, Gabel R, Li W,
Pittermann E, Ugurlucan M, Kundt G,
Zingler C, Titze U, Wang W, Ong LL, Wagner
K, Li RK, Ma N, Steinhoff G (2009)
Intracardiac injection of erythropoietin
induces stem cell recruitment and improves
cardiac functions in a rat myocardial infarc-
tion model. J Cell Mol Med 13:664-679
208. d'Uscio LV, Katusic ZS (2008) Erythropoietin
increases endothelial biosynthesis of tetrahyd-
robiopterin by activation of protein kinase B
alpha/Akt1. Hypertension 52:93-99
209. Singh AK (2011) Is there a deleterious effect
of erythropoietin in end-stage renal disease?
Kidney Int 80:569-571
210. Pfeffer MA, Burdmann EA, Chen CY, Cooper
ME, de Zeeuw D, Eckardt KU, Feyzi JM,
Ivanovich P, Kewalramani R, Levey AS, Lewis
EF, McGill JB, McMurray JJ, Parfrey P,
Parving HH, Remuzzi G, Singh AK, Solomon
SD, Toto R (2009) A trial of darbepoetin alfa
in type 2 diabetes and chronic kidney disease.
N Engl J Med 361:2019-2032
211. Zhang Y, Thamer M, Kaufman JS, Cotter DJ,
Hernan MA (2011) High doses of epoetin do
not lower mortality and cardiovascular risk
among elderly hemodialysis patients with dia-
betes. Kidney Int 80:663-669
212. Weiner DE, Miskulin DC, Seefeld K, Ladik V,
Zager PG, Singh AK, Johnson HK, Meyer
KB (2007) Reducing versus discontinuing
erythropoietin at high hemoglobin levels. J Am
Soc Nephrol 18:3184-3191
213. Corwin HL, Gettinger A, Fabian TC, May A,
Pearl RG, Heard S, An R, Bowers PJ, Burton
P, Klausner MA, Corwin MJ (2007) Efficacy
and safety of epoetin alfa in critically ill
patients. N Engl J Med 357:965-976
214. Bohlius J, Wilson J, Seidenfeld J, Piper M,
Schwarzer G, Sandercock J, Trelle S, Weingart
O, Bayliss S, Brunskill S, Djulbegovic B,
Benett CL, Langensiepen S, Hyde C, Engert
E (2006) Erythropoietin or darbepoetin for
patients with cancer. Cochrane Database Syst
Rev. 3, CD003407
215. Tang YD, Rinder HM, Katz SD (2007)
Effects of recombinant human erythropoietin
on antiplatelet action of aspirin and clopi-
dogrel in healthy subjects: results of a double-
blind, placebo-controlled randomized trial.
Am Heart J 154(494):e491-e497
216. Stohlawetz PJ, Dzirlo L, Hergovich N,
Lackner E, Mensik C, Eichler HG, Kabrna E,
Geissler K, Jilma B (2000) Effects of erythro-
poietin on platelet reactivity and thrombopoi-
esis in humans. Blood 95:2983-2989
217. Held TK, Gundert-Remy U (2010)
Pharmacodynamic effects of haematopoietic
cytokines: the view of a clinical oncologist.
Basic Clin Pharmacol Toxicol 106:210-214
218. Arcasoy MO (2008) Erythropoiesis-
stimulating agent use in cancer: preclinical
and clinical perspectives. Clin Cancer Res
14:4685-4690
Search WWH ::
Custom Search